Research progress on the role of glutamate transporter in the pathogenesis of Parkinson's disease

Abstract

Abstract: The excitotoxicity mediated by glutamate (Glu) is the main pathogenesis of Parkinson’s disease (PD), and the glutamate transporter is the key factor regulating the process of Glu excitotoxicity. Therefore, glutamate transporters may be involved in the pathogenesis of PD and play an important role in the process. Therefore, understanding the role of glutamate transporters in the pathogenesis of PD may provide new ideas for later drug research and development targeting at glutamate transporters.

Key words: Parkinson&apos, s disease, glutamate, glutamate transporter, excitatory amino acid transporters (EAATs), vesicular glutamate transporters (VGLUTs)

CLC Number:

R741

MA Li-fang, LIANG Jian-qing, HE Jian-cheng, SUN Xue, LIANG Peng. Research progress on the role of glutamate transporter in the pathogenesis of Parkinson's disease[J]. Basic & Clinical Medicine, 2021, 41(12): 1813-1817.

References

[1]Dong Y, Xiong M, Chen Y, et al.Plasticity of synaptic transmission in human stem cell-derived neural networks[J].iScience, 2020, 23:100829-100854.
[2]Wu X, Meng X, Tan F, et al.Regulatory mechanism of miR-543-3p on GLT-1 in a mouse model of Parkinson's Disease[J].ACS Chem Neurosci, 2019, 10:1791-1800.
[3]Du X, Li J, Li M, et al.Research progress on the role of type I vesicular glutamate transporter (VGLUT1) in nervous system diseases[J].Cell Biosci, 2020, 10:26-36.
[4]Todd AC, Hardingham GE.The regulation of astrocytic glutamate transporters in health and neurodegenerative diseases[J].Int J Mol Sci, 2020, 21:9607-9637.
[5]Kanai Y, Hediger MA.Primary structure and functional characterization of a high-affinity glutamate transporter[J].Nature, 1992, 360:467-471.
[6]Zhang Y, He X, Meng X, et al.Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model[J].Cell Death Dis, 2017, 8:e2574-e2587.
[7]晏义平, 孙凤艳. 谷氨酸转运体的结构和功能[J].生命科学, 1999, 1:20-22.
[8]米超, 杨欣欣, 齐志鹏, 等. 利鲁唑上调EAATs产生对MPTP诱导的帕金森模型小鼠的保护作用[J].实用药物与临床, 2019, 22:349-353.
[9]Gao T, Wu J, Zheng R, et al.Assessment of three essential tremor genetic loci in sporadic Parkinson's disease in Eastern China[J].CNS Drug Rev, 2020, 26:448-452.
[10]Zhang Y, Meng X, Jiao Z, et al.Generation of a novel mouse model of Parkinson's disease via targeted knock-down of glutamate transporter GLT-1 in the substantia nigra[J].ACS Chem Neurosci, 2020, 11:406-417.
[11]Aoyama K. Glutathione in the brain[J]. Int J Mol Sci, 2021, 22:5010-5014.
[12]Lee M, Dong GK, Hong DK, et al.Role of excitatory amino acid carrier 1 (EAAC1) in neuronal death and neurogenesis after ischemic stroke[J].Int J Mol Sci, 2020, 21:5676-5691.
[13]Piccirillo S, Magi S, Preziuso A, et al.Gateways for glutamate neuroprotection in Parkinson's disease (PD): essential role of EAAT3 and NCX1 revealed in an in vitro model of PD[J].Cells, 2020, 9:2037-2058.
[14]Takayasu Y.Differential roles of glial and neuronal glutamate transporters in purkinje cell synapses[J].J Neurosci, 2005, 25:8788-8793.
[15]Zhou L, Yang L, Li YJ, et al.MicroRNA-128 protects dopamine neurons from apoptosis and upregulates the expression of excitatory amino acid transporter 4 in Parkinson's disease by binding to AXIN1[J].Cell Physiol Biochem, 2018, 51:2275-2289.
[16]Buck SA, Steinkellner T, Aslanoglou D, et al.Vesicular glutamate transporter modulates sex differences in dopamine neuron vulnerability to age-related neurodegeneration[J].Aging Cell, 2021, 20:e13365-e13367.
[17]Rosin DL, Hettinger BD, Lee A, et al.Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function[J].Neurology, 2003, 61:S12-S18.
[18]Zheng X, Huang Z, Zhu Y, et al.Increase in gluta-matergic terminals in the striatum following dopamine depletion in a rat model of Parkinson's disease[J].Neurochem Res, 2019, 44:1079-1089.
[19]Shen H, Marino R, Mcdevitt RA, et al.Genetic deletion of vesicular glutamate transporter in dopamine neurons increases vulnerability to MPTP-induced neurotoxicity in mice[J]. Proc Natl Acad Sci U S A, 2018, 115:E11532-E11541.
[20]Steinkellner T, Zell V, Farino ZJ, et al.Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons[J]. J Clin Invest, 2018, 128:774-788.
[21]Gangarossa G, Guzman M, Prado VF, et al.Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia[J].Neurobiol Dis, 2016, 87:69-79.
[22]Favier M, Pietrancosta N, Mestikawy SE, et al.Leverag-ing VGLUT3 functions to untangle brain dysfunctions[J].Trends Pharmacol Sci, 2021, 42:475-490.